首页> 外文OA文献 >Expression of Integrin A2 Receptor in Human Cord Blood Cd34+Cd38-Cd90+ Stem Cells Engrafting Long-Term in Nod/Scid-Il2rγ(C) Null Mice.
【2h】

Expression of Integrin A2 Receptor in Human Cord Blood Cd34+Cd38-Cd90+ Stem Cells Engrafting Long-Term in Nod/Scid-Il2rγ(C) Null Mice.

机译:人脐血Cd34 + Cd38-Cd90 +干细胞整合蛋白a2受体在Nod / scid-Il2rγ(C)无效小鼠体内长期移植中的表达。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human hematopoietic stem cells reside in the CD34+CD38-CD90+ population in cord blood and bone marrow. However, this cell fraction is heterogeneous, and the phenotype of the rare primitive stem cells remains poorly defined. We here report that primitive cord blood CD34+CD38-CD90+ stem cells, with the ability to reconstitute NOD/SCID-IL2Rγ(c) null mice long term, at 24 weeks after transplantation, can be prospectively isolated at an increased purity by using integrin α2 receptor as an additional stem cell marker. Using a limiting dilution transplantation assay, we found a highly significant enrichment of multilineage reconstituting stem cells in the CD34+CD38-CD90+ cell fraction expressing the integrin α2 receptor, with a frequency of 1/29 cells, as compared to a frequency of 1/157 in the corresponding integrin α2- cells. In line with this, long-term reconstituting stem cells within the cord blood CD34+CD38- cell population were significantly enriched in the integrin α2+ fraction, while stem cells and progenitors reconstituting short-term, at 8-12 weeks, were heterogeneous in integrin α2 expression. Global gene expression profiling revealed that the lineage-marker negative (Lin-) CD34+CD38-CD90+CD45RA- integrin α2+ cell population was molecularly distinct from the integrin α2- cell population and the more mature Lin-CD34+CD38-CD90-CD45RA- cell population. Our findings identify integrin α2 as a novel stem cell marker, which improves prospective isolation of the primitive human hematopoietic stem cells within the CD34+CD38-CD90+ cell population for experimental and therapeutic stem cell applications.
机译:人造血干细胞位于脐带血和骨髓中的CD34 + CD38-CD90 +群体中。然而,该细胞部分是异质的,并且稀有原始干细胞的表型仍然定义不清。我们在这里报告说,原始脐带血CD34 + CD38-CD90 +干细胞具有长期重组NOD /SCID-IL2Rγ(c)无效小鼠的能力,可以在移植后24周内通过使用整联蛋白以提高的纯度进行前瞻性分离α2受体是另外的干细胞标记。使用有限稀释移植测定法,我们发现表达整合素α2受体的CD34 + CD38-CD90 +细胞级分中的多谱系重组干细胞高度丰富,频率为1/29,而频率为1 / 157在相应的整联蛋白α2-细胞中。与此相符,脐带血CD34 + CD38-细胞群中的长期重组干细胞中整合素α2+分数显着富集,而短期重组的干细胞和祖细胞在8-12周时在整合素中异质α2表达。全局基因表达谱分析显示,谱系标记阴性(Lin-)CD34 + CD38-CD90 + CD45RA-整合素α2+细胞群与整合素α2-细胞群和更成熟的Lin-CD34 + CD38-CD90-CD45RA分子上不同-细胞数量。我们的发现将整联蛋白α2鉴定为一种新型干细胞标记,可改善对CD34 + CD38-CD90 +细胞群体内原始人类造血干细胞的前瞻性分离,以用于实验和治疗性干细胞应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号